Intel's Inaction Cited in Denial of its Motion for Attorney’s Fees

Aug 13, 2014

Reading Time : 1 min

The Supreme Court recently relaxed the standard for attorney's fees under Section 285 in Octane Fitness, LLC v. Icon Health & Fitness, Inc., 134 S. Ct. 1749 (2014), and Judge Timothy Dyk — sitting by designation in the Eastern District of Texas — held that even under the relaxed standards of Octane Fitness, Intel was not entitled to recover its attorney’s fees.

Describing Intel's motion as one “primarily based on the fact that Stragent made losing arguments,” Judge Dyk clarified that Stragent’s arguments “were losing arguments, but they were not frivolous.” Of particular concern to Judge Dyk was Intel’s inaction in failing to move for summary judgment of non­infringement on the basis of the claim limitation at issue. Because Intel’s motion for fees was based partly on its criticism of Stragent’s "implausible" theory of infringement, Judge Dyk doubted Intel always believed Stragent’s theory was frivolous when it never moved for summary judgment. Judge Dyk also questioned Intel’s complaints of bad faith discovery when it, “never sought discovery sanctions against Stragent or even a court ruling limiting the scope of discovery.”

Quoting Octane Fitness, Judge Dyk concluded that the case was not exceptional and noted, “this case is not one that ‘stands out from others with respect to the substantive strength of [Stragent’s] litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated.’ Octane, 134 S. Ct. at 1756.”

Stragent, LLC v. Intel Corp., No. 6:11­cv­00421 (E.D. Tex. August 6, 2014,. Order) (Dyk, T.B.).

Share This Insight

Categories

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.